search
Back to results

Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome

Primary Purpose

Postural Orthostatic Tachycardia Syndrome

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Plasma Volume
Exercise Capacity Test - Bicycle
Posture Study
Sponsored by
Vanderbilt University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Postural Orthostatic Tachycardia Syndrome focused on measuring Orthostatic Intolerance, Tachycardia, Orthostatic Hypotension, Sodium

Eligibility Criteria

18 Years - 50 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Premenopausal patients with POTS and healthy volunteers, 18-50 years old, who are non-smokers and free of medications with the potential to influence blood pressure
  • Patients diagnosed with postural tachycardia syndrome by the Vanderbilt Autonomic Dysfunction Center
  • Patients who Increase heart rate ≥30 beats/min with position change from supine to standing (10 minutes)
  • For patients, chronic symptoms consistent with POTS that are worse when upright and get better with recumbence
  • Only female participants are eligible. Since 80-90% of POTS patients are female, and there can be differences in measures with the menstrual cycle, including a small number of males might introduce a significant amount of noise.
  • Able and willing to provide informed consent

Exclusion Criteria:

  • Smokers
  • Overt cause for postural tachycardia, i.e., acute dehydration
  • Significant cardiovascular, pulmonary, hepatic, or hematological disease by history or screening results
  • Positive pregnancy test or breastfeeding
  • Hypertension defined as BP>145/95 off medications when supine or needing antihypertensive medication
  • Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule
  • Unable to give informed consent

Sites / Locations

  • Vanderbilt University Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

High Salt Diet

Low Salt Diet

Arm Description

POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The high sodium diet will provide 300 milliequivalents (mEq) sodium/day.

POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The low sodium diet will provide 10 mEq sodium/day.

Outcomes

Primary Outcome Measures

24hr Urinary Sodium
Amount of sodium excreted in urine over 24hr ending on Day 7
24hr Urinary Dopamine
Amount of dopamine excreted in urine over 24 hours ending on Day 7

Secondary Outcome Measures

Plasma Volume
Plasma volume (PV) was determined by the indicator tracer-dilution technique, using the DAXOR Blood Volume Analyzer (BVA)-100 system (DAXOR Corporation), on Day 7 of the low sodium and high sodium dietary interventions.
Magnitude of Orthostatic Tachycardia
Whether the magnitude of the heart rate increase that occurs in patients with POTS when moving from a supine to an upright position is attenuated by a High Sodium diet relative to a Low Sodium diet. Heart rate was assessed after overnight rest and fasting after midnight, following at least 60 minutes of lying quietly. Heart rate was then measured at intervals after subjects had been standing for up to 30 minutes (as tolerated). Differences between supine and standing values are presented for 5 minutes standing (or maximal stand if <5 minutes) since several patients were unable to stand for 10 minutes. Data in POTS patients were compared to that of Healthy Controls.
Upright Symptom Score
Whether upright symptoms were improved in patients with POTS on a High Sodium diet relative to a Low Sodium diet. Patients were asked to report their standing symptom burden at the end of the Stand portion of the posture study, using the Vanderbilt Orthostatic Symptoms Scale (VOSS). They rated the severity of nine symptoms (palpitations, lightheadedness, mental confusion, blurred vision, shortness of breath, tremulousness, chest discomfort, headache, and nausea) on a scale ranging from a minimum of 0 (reflecting an absence of symptoms) to a maximum score of 10. The sum of the individual symptom scores was used to calculate orthostatic symptom burden for each participant. The lowest possible total score was 0, if a participant scored all 9 questions as 0, and the highest possible score was 90, if a participant scored all 9 questions as 10. Higher scores indicated worse symptoms.
Urinary Sodium Following Change in Dietary Sodium Days 1-2
Urinary sodium excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Urinary Dopamine Following Change in Dietary Sodium Days1-2
Urinary dopamine excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Urinary Sodium Following Change in Dietary Sodium Days 2-3
Urinary sodium excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Urinary Sodium Following Change in Dietary Sodium Days 3-4
Urinary sodium excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Urinary Sodium Following Change in Dietary Sodium Days 4-5
Urinary sodium excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets
Urinary Sodium Following Change in Dietary Sodium Days 5-6
Urinary sodium excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Urinary Dopamine Following Change in Dietary Sodium Days 2-3
Urinary dopamine excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Urinary Dopamine Following Change in Dietary Sodium Days 3-4
Urinary dopamine excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Urinary Dopamine Following Change in Dietary Sodium Days 4-5
Urinary dopamine excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Urinary Dopamine Following Change in Dietary Sodium Days 5-6
Urinary dopamine excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.

Full Information

First Posted
March 22, 2012
Last Updated
December 27, 2021
Sponsor
Vanderbilt University Medical Center
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
search

1. Study Identification

Unique Protocol Identification Number
NCT01563107
Brief Title
Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome
Official Title
Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
December 2021
Overall Recruitment Status
Completed
Study Start Date
March 2012 (undefined)
Primary Completion Date
December 2020 (Actual)
Study Completion Date
December 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vanderbilt University Medical Center
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Patients with Postural Tachycardia Syndrome (POTS) may not adequately expand their plasma volume in response to a high sodium diet. Mechanisms involved in the regulation of plasma volume, such as the renin-angiotensin-aldosterone system and renal dopamine (DA), may be impaired in POTS and may respond inappropriately to changes in dietary sodium. The investigators propose that the changes in urinary sodium and dopamine excretion caused by consuming low-sodium and high-sodium diets will be different between patients with POTS and healthy volunteers. The purpose of this study is to determine (1) whether changes in dietary sodium level appropriately influence sodium excretion in POTS; (2) whether changes in dietary sodium level appropriately influence DA excretion in POTS; (3) whether a high dietary sodium level appropriately expands plasma volume in POTS; and (4) whether patients with POTS have improvements in their orthostatic tachycardia and symptoms as a result of a high dietary sodium level.
Detailed Description
Study Day 1 Start 150 mEq Na+/day diet (POTS patients as inpatients; healthy control subjects with Clinical Research Center(CRC)- provided outpatient diet); consume 1.5-2 liters of water per day Start a 24hour (24hr) urine collection (for sodium (Na+), potassium (K+), creatinine (Cr), fractionated catecholamines) Blood work Study Days 2-5 Continue 24hr urine collection Start STUDY DIET (10 mEq Na+/day or 300 mEq Na+/day in a random order) after 3 meals of 150 mEq Na+/day are complete; consume 1.5-2 liters of water per day On Day 5, a 24 hr Holter combined ECG monitor and BP monitor will be placed on the subjects. Study Day 6 Continue STUDY DIET; consume 1.5-2 liters of water per day Remove 24hr Holter combined ECG monitor and BP monitor from subject Continue 24hr urine collection (for Na+, K+, Cr, fractionated catecholamines) Admit to CRC in afternoon (healthy control subjects only, as POTS patients will have already been admitted). Each subject will spend the night in the CRC and remain supine Nothing by mouth (NPO) after midnight for study next day Study Day 7 Awaken early (~6am) to void (still collecting 24hr urine) Patient returns to bed, IV catheter inserted Posture Study (in morning; between 7-8am ideally) Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes We will draw blood in each body position to measure electrolytes and hormones that regulate blood pressure and blood volume Subjects will rate symptoms during supine period and at end of stand using Vanderbilt Orthostatic Symptoms Score (VOSS) Total Blood Volume (DAXOR)- using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation blood samples drawn through IV catheter before injection and for ~30 minutes post-injection (total - 25 ml) This will be done after supine assessment, but before standing the subject up Exercise Capacity Test (in the afternoon) Will estimate maximal oxygen consumption (VO2 max). This test will be conducted on a stationary bicycle. Effort will be gradually increased while expired air is measured during exhaustive physical work. All procedures are repeated at least a month later with the 2nd level of dietary salt. (Randomized to high or low salt in the first phase, the second phase is the remaining level)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postural Orthostatic Tachycardia Syndrome
Keywords
Orthostatic Intolerance, Tachycardia, Orthostatic Hypotension, Sodium

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Randomization tables will be used to determine whether the 10 milliequivalents (mEq) sodium/day or 300 mEq sodium/day diet will be consumed first. Both diets will be completed on each subject (randomized crossover study), so all of the study procedures (after screening) will be repeated.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
38 (Actual)

8. Arms, Groups, and Interventions

Arm Title
High Salt Diet
Arm Type
Experimental
Arm Description
POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The high sodium diet will provide 300 milliequivalents (mEq) sodium/day.
Arm Title
Low Salt Diet
Arm Type
Experimental
Arm Description
POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The low sodium diet will provide 10 mEq sodium/day.
Intervention Type
Radiation
Intervention Name(s)
Plasma Volume
Other Intervention Name(s)
DAXOR
Intervention Description
Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
Intervention Type
Procedure
Intervention Name(s)
Exercise Capacity Test - Bicycle
Other Intervention Name(s)
VO2 Max (maximal oxygen consumption)
Intervention Description
subjects breathe room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
Intervention Type
Procedure
Intervention Name(s)
Posture Study
Other Intervention Name(s)
Standing Orthostatic Challenge
Intervention Description
Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
Primary Outcome Measure Information:
Title
24hr Urinary Sodium
Description
Amount of sodium excreted in urine over 24hr ending on Day 7
Time Frame
Day 6 am - Day 7 am for each dietary sodium level
Title
24hr Urinary Dopamine
Description
Amount of dopamine excreted in urine over 24 hours ending on Day 7
Time Frame
Between Day 6 am - Day 7 am of each dietary sodium level
Secondary Outcome Measure Information:
Title
Plasma Volume
Description
Plasma volume (PV) was determined by the indicator tracer-dilution technique, using the DAXOR Blood Volume Analyzer (BVA)-100 system (DAXOR Corporation), on Day 7 of the low sodium and high sodium dietary interventions.
Time Frame
after 7 days of each dietary sodium level
Title
Magnitude of Orthostatic Tachycardia
Description
Whether the magnitude of the heart rate increase that occurs in patients with POTS when moving from a supine to an upright position is attenuated by a High Sodium diet relative to a Low Sodium diet. Heart rate was assessed after overnight rest and fasting after midnight, following at least 60 minutes of lying quietly. Heart rate was then measured at intervals after subjects had been standing for up to 30 minutes (as tolerated). Differences between supine and standing values are presented for 5 minutes standing (or maximal stand if <5 minutes) since several patients were unable to stand for 10 minutes. Data in POTS patients were compared to that of Healthy Controls.
Time Frame
Supine and upright heart rate were measured after 6 days of each dietary sodium level
Title
Upright Symptom Score
Description
Whether upright symptoms were improved in patients with POTS on a High Sodium diet relative to a Low Sodium diet. Patients were asked to report their standing symptom burden at the end of the Stand portion of the posture study, using the Vanderbilt Orthostatic Symptoms Scale (VOSS). They rated the severity of nine symptoms (palpitations, lightheadedness, mental confusion, blurred vision, shortness of breath, tremulousness, chest discomfort, headache, and nausea) on a scale ranging from a minimum of 0 (reflecting an absence of symptoms) to a maximum score of 10. The sum of the individual symptom scores was used to calculate orthostatic symptom burden for each participant. The lowest possible total score was 0, if a participant scored all 9 questions as 0, and the highest possible score was 90, if a participant scored all 9 questions as 10. Higher scores indicated worse symptoms.
Time Frame
Upright symptoms were assessed on the 6th day of low or high sodium diet.
Title
Urinary Sodium Following Change in Dietary Sodium Days 1-2
Description
Urinary sodium excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Time Frame
24 hour collections ending on Day 2 of each diet phase
Title
Urinary Dopamine Following Change in Dietary Sodium Days1-2
Description
Urinary dopamine excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Time Frame
24 hour collections ending on Day 2 of each dietary sodium phase
Title
Urinary Sodium Following Change in Dietary Sodium Days 2-3
Description
Urinary sodium excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Time Frame
24 hour collections ending on Day 3 of each diet phase
Title
Urinary Sodium Following Change in Dietary Sodium Days 3-4
Description
Urinary sodium excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Time Frame
24 hour collections ending on Day 4 of each diet phase
Title
Urinary Sodium Following Change in Dietary Sodium Days 4-5
Description
Urinary sodium excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets
Time Frame
24 hour collections ending on Day 5 of each diet phase
Title
Urinary Sodium Following Change in Dietary Sodium Days 5-6
Description
Urinary sodium excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Time Frame
24 hour collections ending on Day 6 of each diet phase
Title
Urinary Dopamine Following Change in Dietary Sodium Days 2-3
Description
Urinary dopamine excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Time Frame
24 hour collections ending on Day 3 of each dietary sodium phase
Title
Urinary Dopamine Following Change in Dietary Sodium Days 3-4
Description
Urinary dopamine excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Time Frame
24 hour collections ending on Day 4 of each dietary sodium phase
Title
Urinary Dopamine Following Change in Dietary Sodium Days 4-5
Description
Urinary dopamine excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Time Frame
24 hour collections ending on Day 5 of each dietary sodium phase
Title
Urinary Dopamine Following Change in Dietary Sodium Days 5-6
Description
Urinary dopamine excretion will be measured every 24 hours as the participant adapts from the 150 mEq Na/day diet to the 10 and 300 mEq Na/day diets.
Time Frame
24 hour collections ending on Day 6 of each dietary sodium phase

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Premenopausal patients with POTS and healthy volunteers, 18-50 years old, who are non-smokers and free of medications with the potential to influence blood pressure Patients diagnosed with postural tachycardia syndrome by the Vanderbilt Autonomic Dysfunction Center Patients who Increase heart rate ≥30 beats/min with position change from supine to standing (10 minutes) For patients, chronic symptoms consistent with POTS that are worse when upright and get better with recumbence Only female participants are eligible. Since 80-90% of POTS patients are female, and there can be differences in measures with the menstrual cycle, including a small number of males might introduce a significant amount of noise. Able and willing to provide informed consent Exclusion Criteria: Smokers Overt cause for postural tachycardia, i.e., acute dehydration Significant cardiovascular, pulmonary, hepatic, or hematological disease by history or screening results Positive pregnancy test or breastfeeding Hypertension defined as BP>145/95 off medications when supine or needing antihypertensive medication Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule Unable to give informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alfredo Gamboa, MD
Organizational Affiliation
Vanderbilt University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome

We'll reach out to this number within 24 hrs